Close Menu

restructuring

The firm's Pharmaceutical Divisions will be primarily affected by the job cuts and transfers. The program is expected to result in annual cost savings of CHF2.4 billion ($2.4 billion) for Roche.

The firm's lab services revenues were hurt by lower sample volume, but were partially offset by a higher average price per sample. Celera also announced a restructuring program intended to cut costs by $10 million next year.

The firm hopes to cut its monthly burn rate 32 percent as it pushes forward with plans to launch second-generation miRview tests.

The firm will cut another 14 positions, on top of the previously announced 40 jobs, as it aims to reduce its operating costs.

A streamlining of its Life Sciences and Clinical Labs operations is expected to result in a reduction of annualized operating expenditures of $4 million.

As the firm completes the first phase of its restructuring, it reported a 51 percent increase in revenues and appointed a new CEO.

The firm expects to incur approximately $667,000 in restructuring costs.

The firm has decided to focus on growing its molecular diagnostics services business rather than continuing to pursue a deal with a partner.

The firm is pressing ahead with its plans to focus on the molecular diagnostics market. Part of its restructuring includes the departure of J. William Efcavitch as chief technology officer.

The firm reported that it had not received any revenues in the quarter tied to system sales. It had announced separately yesterday that it will reposition its focus on the molecular diagnostics industry.

Pages

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.